Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab | BMC Cancer | Full Text

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab | BMC Cancer | Full Text

Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multi...

Authors:Sergey M. Alexeev, Andrey V. Khorinko, Guzel Z. Mukhametshina, Konstantin G. Shelepen, Olga N. Burdaeva, Sergey A. Kulik, Chiradoni Thugappa Satheesh, Kirti Srivastava, Mummaneni Vikranth, Fedor Kryukov, Anastasia N. Paltusova, Mariya S. Shustova and Roman A. Ivanov

Citation:BMC Cancer 2020 20:783

Content type:Research article

 

Published on: 20 August 2020

• ViewFull Text
 
• ViewPDF